高级检索
当前位置: 首页 > 详情页

Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Nuclear Medicine, West China Hospital, Sichuan University, 610041, Chengdu, China [2]Department of Biochemistry & Molecular Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China [3]Institute of Urology, Department of Urology, West China Hospital, Sichuan University, 610041, Chengdu, China
出处:
ISSN:

关键词: Prostate cancer Prostate specific membrane antigen Radionuclide imaging Radionuclide therapy PSMA-targeted BCR

摘要:
Prostate cancer (PCa) is the most common sex-related malignancy with high mortality in men worldwide. Prostate-specific membrane antigen (PSMA) is overexpressed on the surface of most prostate tumor cells and considered a valuable target for both diagnosis and therapy of prostate cancer. A series of radiolabeled agents have been developed based on the featured PSMA ligands in the previous decade and have demonstrated promising outcomes in clinical research of primary and recurrent PCa. Furthermore, the inspiring response and safety of lutetium-177-PSMA-617 (177Lu-PSMA-617) radiotherapy represent the potential for expanded therapeutic options for metastatic castration-resistant PCa. Retrospective cohort studies have revealed that radiolabeled PSMA agents are the mainstays of the current success, especially in detecting prostate cancer with metastasis and biochemical recurrence. This review is intended to present a comprehensive overview of the current literature on PSMA ligand-based agents for both radionuclide imaging and therapeutic approaches, with a focus on those that have been clinically adopted. PSMA-based diagnosis and therapy hold great promise for improving the clinical management of prostate cancer. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版
大类 | 3 区 医学
小类 | 3 区 药物化学
最新[2023]版
大类 | 4 区 医学
小类 | 4 区 药物化学
第一作者:
第一作者机构: [1]Department of Nuclear Medicine, West China Hospital, Sichuan University, 610041, Chengdu, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Nuclear Medicine, West China Hospital, Sichuan University, 610041, Chengdu, China [*1]Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan 610041, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号